The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
December 11th 2023
Phase 3 data show patients with obesity who maintained tirzepatide from weeks 36 to 88 continued significant weight loss versus patients switched to placebo.
Advancing Cardiology Care Through Professional Education®: The 6th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
View More
Transfusion-Related Iron Overload–Evidence-Based Approaches to Improve Chelation Outcomes
View More
Community Practice Connections™: Expert Perspectives on the Evolving Treatment Paradigm in Heart Failure Management
View More
Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias
View More
Medical Crossfire®: Updates in Continuous Glucose Monitoring—Having the Important Conversations With Your Patients
View More
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
View More
Don't Miss a Beat: SELECT, DAPA-MI, & AHA 2023
November 13th 2023In this episode, hosts sit down between sessions at AHA 2023 to discuss the landmark SELECT trial, their interpretation of the data, and its implications for care moving forward. Later in the episode, hosts break down the DAPA-MI trial.
Quality of Life Is Worse for Patients with Heart Failure than Many Cancers, Study Finds
November 12th 2023Participants with heart failure measured lower on physical and mental component scores than patients with lung, colon, breast, or prostate cancer, highlighting their worser health-related quality of life.
Abelacimab Significantly Reduces Bleeding in People with Atrial Fibrillation, Study Finds
November 12th 2023Presented at AHA 2023, the topline analysis of the phase 2 AZALEA-TIMI 71 trial showed abelacimab significantly reduced bleeding in people with Afib at risk of stroke, compared with rivaroxaban.